CLINICAL_TRIALS ClinicalTrials.gov record update

An Open-Label Phase III Clinical Trial to Study the Immunogenicity and Tolerability of GARDASIL®9 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Adult Women (27- to 45-Year-Olds) Compared to Young Adult Women (16 to 26 Year Olds)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT03158220
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:37:30.629751+00:00
Published At: 2019-11-21T00:00:00+00:00
Record Updated At: 2019-11-21
Results Posted At: 2019-11-21
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Cervical Cancer", "Vulvar Cancer", "Vaginal Cancer", "Genital Warts", "Human Papillomavirus Infection"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2019-11-21"
protocolSection.identificationModule.nctId: "NCT03158220"
protocolSection.identificationModule.officialTitle: "An Open-Label Phase III Clinical Trial to Study the Immunogenicity and Tolerability of GARDASIL\u00ae9 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Adult Women (27- to 45-Year-Olds) Compared to Young Adult Women (16 to 26 Year Olds)"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE3"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2019-11-21"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.